RTT

Helsinn Group and Italfarmaco announce oral presentation of NEPA (netupitant and palonosetron) data at ESMO Virtual Congress 2020

Friday, September 18, 2020 - 8:00am

Whilst generally considered safe, even short-term use of DEX is associated with various side effects, including transient elevations in glucose, insomnia, anxiety, and gastric upset.

Key Points: 
  • Whilst generally considered safe, even short-term use of DEX is associated with various side effects, including transient elevations in glucose, insomnia, anxiety, and gastric upset.
  • There is also evidence to suggest that DEX may reduce the efficacy of most immunotherapies and cellular therapies if used concurrently.
  • Dr Silvia Sebastiani, Helsinn Head of Medical Affairs, commented: Our aim is to always improve the quality of life for cancer patients.
  • Title: Two simplified dexamethasone (DEX)-sparing regimens with NEPA for the prevention of emesis caused by cisplatin (DDP): a phase III, controlled, non-inferiority trial

PolyU designs new dual-task exercise for stroke patients to effectively reduce the risk of falls and fall-related injuries

Friday, September 18, 2020 - 3:15am

However, the rate of falling remains high (up to 73%) after the stroke survivors have returned to community living.

Key Points: 
  • However, the rate of falling remains high (up to 73%) after the stroke survivors have returned to community living.
  • [3]-[13] "Fall is one of the most common complications in stroke patients during the post-stroke period, frequently caused by poor dual-task mobility.
  • Only five falls were reported in the dual-task group while there were 20 falls in the control group," Professor PANG said.
  • Higher Incidence of Falls in Long-Term Stroke Survivors Than in Population Controls: Depressive Symptoms Predict Falls After Stroke.

PolyU designs new dual-task exercise for stroke patients to effectively reduce the risk of falls and fall-related injuries

Friday, September 18, 2020 - 3:02am

However, the rate of falling remains high (up to 73%) after the stroke survivors have returned to community living.

Key Points: 
  • However, the rate of falling remains high (up to 73%) after the stroke survivors have returned to community living.
  • [3]-[13] "Fall is one of the most common complications in stroke patients during the post-stroke period, frequently caused by poor dual-task mobility.
  • Only five falls were reported in the dual-task group while there were 20 falls in the control group," Professor PANG said.
  • Higher Incidence of Falls in Long-Term Stroke Survivors Than in Population Controls: Depressive Symptoms Predict Falls After Stroke.

Ufovax Announces Its Self-Assembling NanoParticles as the Next-Generation Vaccine Solution for COVID-19

Friday, September 18, 2020 - 12:32am

Ufovax holds an exclusive global license to the Scripps Intellectual Property covering the platform and several vaccines, including COVID-19.

Key Points: 
  • Ufovax holds an exclusive global license to the Scripps Intellectual Property covering the platform and several vaccines, including COVID-19.
  • In a publication submitted Monday, September 14 (now available on the bioRxiv preprint server ), the authors present a systematic study on rational vaccine design and evaluation of vaccine response in mice.
  • In particular, Zhu and his team propose a new spike antigen design (S2GHR2) and displayed it on several SApNPs as COVID-19 vaccine candidates.
  • In practice, we have seen similar performance from the Merck HPV Gardasil vaccine which is essentially a protein nanoparticle vaccine.

American Diabetes Association® Empowers Youth at Home Nationwide through Project Power

Thursday, September 17, 2020 - 10:05pm

ADA's Project Power, formerly known as Power Up, connects and empowers youth to make healthy lifestyle choices to develop lifelong habits and encourages youth to develop sustainable healthy household habits.

Key Points: 
  • ADA's Project Power, formerly known as Power Up, connects and empowers youth to make healthy lifestyle choices to develop lifelong habits and encourages youth to develop sustainable healthy household habits.
  • Youth participants will receive a special ADA Project Power Box and Activity Journal delivered to their homes.
  • The American Diabetes Association (ADA) is the nation's leading voluntary health organization fighting to bend the curve on the diabetes epidemic and help people living with diabetes thrive.
  • Join the fight with us on Facebook (American Diabetes Association ), Twitter ( @AmDiabetesAssn ) and Instagram ( @AmDiabetesAssn ).

Checkpoint Therapeutics Announces $20.0 Million Bought Deal Offering

Thursday, September 17, 2020 - 10:27pm

The closing of the offering is expected to occur on or about September 22, 2020, subject to satisfaction of customary closing conditions.

Key Points: 
  • The closing of the offering is expected to occur on or about September 22, 2020, subject to satisfaction of customary closing conditions.
  • H.C. Wainwright & Co. is acting as the sole book-running manager for the offering.
  • The gross proceeds to Checkpoint, before deducting underwriting discounts and commissions and offering expenses and assuming no exercise of the underwriter's option to purchase additional common stock, are expected to be approximately $20.0 million.
  • Checkpoint Therapeutics, Inc. (Checkpoint) is a clinical-stage immunotherapy and targeted oncology company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers.

Zenith Provides Update Regarding Extension of its Filing Calendar

Friday, September 18, 2020 - 12:00am

Zenith continues to expect that it will file the Annual Filings on or before October 12, 2020.

Key Points: 
  • Zenith continues to expect that it will file the Annual Filings on or before October 12, 2020.
  • The Company does not expect to file its Interim Filings by the regular filing deadline of September 29, 2020.
  • Zenith Capital Corp. is a biotechnology investment company originally spun out of Resverlogix Corp. (TSX: RVX) in 2013.
  • The lead compound, ZEN-3694, is in clinical development for metastatic Castration Resistant Prostate Cancer (mCRPC) and Triple Negative Breast Cancer.

Junshi Biosciences Receives Orphan Drug Designation from the U.S. FDA for Toripalimab for the Treatment of Soft Tissue Sarcoma

Thursday, September 17, 2020 - 11:00pm

The FDA has previously granted Orphan Drug designation for Toripalimab for the treatment of mucosal melanoma and nasopharyngeal carcinoma.

Key Points: 
  • The FDA has previously granted Orphan Drug designation for Toripalimab for the treatment of mucosal melanoma and nasopharyngeal carcinoma.
  • Soft tissue sarcoma is a rare heterogeneous tumor with complex pathological types and obvious tumor heterogeneity.
  • The current clinical treatment of soft tissue sarcoma mainly uses cytotoxic anti-tumor drugs, which have significant adverse reactions and poor tolerance.
  • Toripalimab for the treatment of nasopharyngeal carcinoma was granted the Breakthrough Therapy designation by the FDA in September 2020.

BeiGene Presents Data at ESMO Virtual Congress 2020 on Phase 3 Trial of Tislelizumab in First-Line Non-Squamous Non-Small Cell Lung Cancer and Phase 2 Trial of Pamiparib in Advanced Ovarian Cancer

Thursday, September 17, 2020 - 11:05pm

Our hope is to advance our broad tislelizumab development program in lung cancer to potentially improve treatment outcomes for the most prevalent cancer, both globally and in China.

Key Points: 
  • Our hope is to advance our broad tislelizumab development program in lung cancer to potentially improve treatment outcomes for the most prevalent cancer, both globally and in China.
  • Pamiparib demonstrated strong antitumor activity in patients with advanced ovarian cancer, having achieved clinically meaningful and durable responses in both platinum-sensitive and platinum-resistant patients with BRCA1/2 mutation.
  • The preliminary results presented at ESMO 2020 were from a Phase 2 dose-expansion portion of a Phase 1/2 trial of pamiparib in patients with advanced ovarian cancer, fallopian cancer, and primary peritoneal cancer or advanced triple negative breast cancer (NCT03333915).
  • To learn more about the data presented at the ESMO Virtual Congress 2020 and BeiGenes clinical pipeline, visit our virtual booth at https://beigenemedical.eu/ .

Vitamin C Supplements Market and Competitive Landscape & Pandemic Recovery Analysis 2020 - Technavio

Thursday, September 17, 2020 - 11:30pm
Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20200917005758/en/
    Technavio has announced its latest market research report titled Global Vitamin C Supplements Market 2020-2024 (Graphic: Business Wire)
    The research is classified into seven sections vitamin C supplements market landscape, market sizing, five force analysis, customer landscape, geographic landscape, drivers, challenges, and trends, and vendor landscape and analysis.
  • Vitamin C Supplements Region Growth: Find out the highest and slowest growth of regions for vitamin C supplements market.
  • Vitamin C Supplements Market Valuations: Find out the global market size for vitamin C supplements in 2019 and how the market will advance from 2020 to 2024.
  • Vitamin C Supplements Market Share: Find out the global market shares for key vitamin C supplements distribution channels.